Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Emmaus Life Sciences ( (EMMA) ).
On December 24, 2025, Emmaus Life Sciences entered into a License and Exclusive Distribution Agreement granting NeoImmuneTech an exclusive license to market, sell, and distribute Endari and any generic equivalents for sickle cell disease in the U.S., its territories and possessions, and Canada in exchange for an upfront payment and royalties on sales. The agreement, announced publicly on December 30, 2025, will be coupled with an exclusive supply arrangement under which Emmaus will manufacture Endari for NeoImmuneTech at cost plus margin, while Emmaus facilitates the transfer of selected U.S. sales staff to its partner and retains rights to Endari outside North America and outside sickle cell disease. The effective date of the deal is contingent on NeoImmuneTech securing required regulatory approvals and meeting other conditions, with the contract allowing termination if these are not met by October 1, 2026 or if performance thresholds are missed later, underscoring both Emmaus’s strategy to redeploy resources toward higher-growth regions and NeoImmuneTech’s aim to leverage Endari’s U.S. commercial infrastructure to support its broader pipeline.
Spark’s Take on EMMA Stock
According to Spark, TipRanks’ AI Analyst, EMMA is a Neutral.
Emmaus Life Sciences’ overall stock score is heavily influenced by its poor financial performance and valuation metrics. The company’s declining revenues, persistent losses, and high leverage are significant concerns. Additionally, weak technical indicators and a negative P/E ratio further contribute to the low score. The absence of earnings call data and corporate events means these factors do not impact the score.
To see Spark’s full report on EMMA stock, click here.
More about Emmaus Life Sciences
Emmaus Life Sciences, Inc. is a commercial-stage biopharmaceutical company and a leader in the treatment of sickle cell disease. Its lead product, Endari, a prescription-grade L-glutamine oral powder approved by the U.S. FDA in 2017, is indicated to reduce acute complications of sickle cell disease in adults and children aged five and older and is approved in multiple Middle Eastern countries and available on a named-patient or early-access basis in several European and Gulf markets.
Average Trading Volume: 96,911
Technical Sentiment Signal: Strong Sell
Current Market Cap: $830.3K
Find detailed analytics on EMMA stock on TipRanks’ Stock Analysis page.